Detalhe da pesquisa
1.
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Blood Adv
; 7(7): 1137-1145, 2023 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36375046
2.
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Cancer Cell
; 41(1): 210-225.e5, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36584673
3.
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 39(23): 2605-2616, 2021 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909455
4.
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Nat Biotechnol
; 39(12): 1537-1547, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294911
5.
Liquid biopsy in lymphoma: Molecular methods and clinical applications.
Cancer Treat Rev
; 91: 102106, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33049623
6.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
J Clin Oncol
; 36(28): 2845-2853, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125215
7.
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.
Sci Transl Med
; 8(364): 364ra155, 2016 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27831904
8.
Reply to J. Wang et al.
J Clin Oncol
; 37(9): 755-757, 2019 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753108